We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Taro Pharmaceutical Industries Ltd. reported today that on July 19, 2006 it received a Staff Determination from the Listing Qualifications Department of The Nasdaq Stock Market.
Eli Lilly and Company and Alcon, Inc. announced that they have signed a long-term agreement to co-promote ruboxistaurin mesylate (proposed brand name, Arxxant, pronounced ark-ZONT) in the U.S. and Puerto Rico.
The European Medicines Agency informed Roche that the filing for a new indication in Europe for the oral cancer drug Xeloda (capecitabine) in combination with another chemotherapy (cisplatin) for the treatment of patients with advanced gastric (stomach) cancer has been accepted.
CytoDyn, Inc., a development stage biotechnology company, and UTEK Corporation, a specialty finance company focused on technology transfer, announced that CytoDyn has acquired Advanced Influenza Technologies, Inc. (AIT), a wholly owned subsidiary of UTEK, in a stock transaction.
Nastech Pharmaceuticals has received a "not approvable" letter from the FDA for its abbreviated new drug application (ANDA) for a generic nasal treatment for osteoporosis was rejected by the FDA, the company said June 13.
The FDA is in disarray, beset by political and industry influences and hampered by insufficient funding to protect public health, a study of agency scientists concludes.